FSD Pharma Inc., through its subsidiaries, operates as a pharmaceutical research and development company. Its lead candidate includes FSD-201 that is in the Phase II clinical trial to treat COVID-19 disease. The company also focuses on Lucid-PSYCH, a psychoactive molecule identified for the potential treatment of neuropsychiatric disorders, such as depressive disorder; and Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. FSD Pharma Inc. was founded in 1998 and is headquartered in Toronto, Canada.
The current price of HUGE is $0.09 USD — it has decreased by -98.62% in the past 24 hours. Watch FSD Pharma stock price performance more closely on the chart.
What is FSD Pharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange FSD Pharma stocks are traded under the ticker HUGE.
What is FSD Pharma revenue for the last year?▼
FSD Pharma revenue for the last year amounts to 0 USD.